Clinical Trials | An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants with Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants with Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
The University of Virginia seeks women age 18 years and older to participate in a maintenance clinical trial. You may be eligible for this study if you have relapsed platinum sensitive ovarian cancer and have completed 1-2 lines of chemotherapy within the last 8 weeks. This study will test an investigational medication called COM701 in treating your cancer. If you participate in this study, you may be randomized (assigned by chance) to one of two treatment arms (COM701 versus Placebo). You will have twice as likely chance of getting COM701. Once randomized, you will be given treatment intravenously (IV) every 3 weeks. If you participate in this study, you may be undergoing study treatment for up to two years. This study will include: blood draws, tumor imaging assessments, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT06888921